Investing.com says InvestingPro’s Fair Value analysis flagged Vaxcyte (NASDAQ: PCVX) as overvalued in September 2024: it reports a share price of $111.58 and a Fair Value estimate of $62.99, implying 43.55% downside. Investing.com’s October 2026 retrospective says PCVX later stood at $56.90, a 49.19% drop from the earlier price. Those figures make the story striking, but the available evidence does not independently verify the original dated model estimate or matching historical prices. Investing.com’s retrospective is the source for the prediction and performance figures.
What InvestingPro reportedly said about Vaxcyte
According to Investing.com’s October 1, 2026 retrospective, InvestingPro’s Fair Value analysis rated Vaxcyte as overvalued in September 2024. Investing.com reports these figures:
| Figure | Investing.com’s account |
|---|---|
| Vaxcyte share price in September 2024 | $111.58 per share |
| InvestingPro Fair Value estimate | $62.99 per share |
| Implied downside from that price to Fair Value | 43.55% |
| Later share price | $56.90 per share |
| Reported decline | 49.19% |
These are figures reported by Investing.com, not independently verified historical records. The rounded endpoints, $111.58 and $56.90, imply a decline of about 49.0%; they do not reproduce 49.19% exactly. The small difference may reflect more precise underlying prices or a calculation detail that Investing.com does not state.
Does that prove InvestingPro predicted the decline?
Not on its own. The retrospective describes a historical estimate, but the available sources do not include an archived InvestingPro model record timestamped in September 2024 or an independent historical price series confirming the relevant price points. That leaves the key claim—what investors could see at the time and how the forecast was calculated—unverified.
#1 Best Overall
A decline that ends near a model’s estimated Fair Value is not, by itself, evidence that the model reliably forecast the timing or direction of future prices. To assess a prediction, a reader would need the original estimate and valuation date, its assumptions and model version, and a clearly defined forecast horizon and comparable outcome prices. Without that record, this is best described as Investing.com’s retrospective account of a model call, not an independently audited prediction.
What Vaxcyte’s business and pipeline add to the context
A clinical-stage company, not a marketed-vaccine business
Vaxcyte describes itself as a clinical-stage vaccine company developing vaccines for bacterial infectious diseases. Its 2025 Form 10-K says it had no products approved for commercial sale. The filing reports net losses of $766.6 million in 2025 and $463.9 million in 2024, and an accumulated deficit of $2.2 billion as of December 31, 2025. Those issuer-reported figures describe the company’s financial position; they do not establish why its shares moved or whether a Fair Value estimate was accurate. Vaxcyte’s SEC-filed 2025 Form 10-K
VAX-31 milestones were expectations, not completed outcomes
In an August 5, 2026 update, Vaxcyte said its three adult VAX-31 Phase 3 OPUS trials were fully enrolled. The company expected OPUS-1 topline data in the fourth quarter of 2026 and results from OPUS-2 and OPUS-3 in the first half of 2027. These were company plans and expectations at the time of the update, not reported trial results. Vaxcyte also said 6,191 adults had been dosed across the three Phase 3 trials, approximately 3,500 of whom received VAX-31, and reported $2.5 billion in cash, cash equivalents and investments as of June 30, 2026. A cash balance is not a valuation of the company’s shares. Vaxcyte’s August 5, 2026 business update
Vaxcyte’s homepage describes VAX-31 as designed to increase coverage of pneumococcal disease in adults and children. That is the company’s description of a vaccine candidate, not evidence of clinical effectiveness or regulatory approval. Vaxcyte
Rank #3
How to evaluate a retrospective stock-prediction claim
Before treating any “called the drop” story as proof of forecasting skill, check the record on five points:
- Timestamp and auditability: Is the original estimate preserved with a date, or is it described only in a later article?
- Price definitions: Are the starting and ending figures closing prices, intraday prices, or adjusted prices, and do their dates match the claimed period?
- Forecast horizon: Did the estimate specify when the target should be reached, and is the outcome measured at that horizon?
- Method disclosure: Are the valuation date, assumptions, inputs and model version available?
- Other developments: Are company, clinical, financing and broader market events documented, rather than asserted as causes of the price move?
For the September 2024 Vaxcyte claim, the absent archived estimate and independent matching price record are the central limitations. Investing.com’s retrospective supplies the forecast and price figures; Vaxcyte’s filings and company updates establish business and clinical context, not whether the forecast was accurate.
Quick Recap
Rank #4
- Used Book in Good Condition
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
